指南与共识甲状腺核医学核素与放射性配体治疗

中国放射性碘难治性分化型甲状腺癌管理指南(2025版)

Chinese management guidelines for radioactive iodine-refractory differentiated thyroid cancer (2025 edition).
指南 / 共识 · Eur J Nucl Med Mol Imaging · 2025-03-25

该指南由中国制定,针对放射性碘难治性分化型甲状腺癌(RAIR-DTC)的临床诊疗,采用GRADE方法对证据进行定量与定性评价,形成26个临床问题和35条推荐,内容涵盖定义标准、预测识别、治疗前评估、系统治疗与手术联合、再分化后RAI治疗及分子影像的应用。

要点

  • 指南优化了RAIR-DTC的定义标准,并基于分子检测、动态生化变化和多模态影像进行预测与识别。
  • 强调治疗前全面临床评估以实现个体化决策,并更新了系统治疗联合手术及再分化后RAI治疗的推荐。
  • 分子影像在RAIR-DTC的治疗前评估和疗效反应评价中具有独特作用。

核心结论

  • 本指南更新并制定了基于证据的推荐,旨在为中国RAIR-DTC患者的临床诊疗提供科学、严谨和全面的指导。
  • 指南希望与国外同行分享,并期待进一步的评论和建议。

研究设计与样本

  • 本指南为指南类文件,由指南制定组制定,编辑过程完全独立于指南制定组。
  • 结构化的临床问题来源于临床诊疗过程,并参考了研究、既往指南、专家共识和系统综述等。
  • 采用GRADE方法对证据进行定量和定性评价。

主要发现

  • 指南共解决26个临床问题,形成35条推荐。
  • 指南优化了RAIR-DTC的定义标准,预测和识别基于包括分子检测、动态生化变化和多模态影像在内的证据。
  • 指南强调治疗前全面临床评估并针对个体化决策进行定制,并回顾和更新了系统治疗与手术联合、再分化后RAI治疗。
  • 分子影像在RAIR-DTC的治疗前评估和疗效反应评价中发挥独特作用。

关键数值与推荐

  • 指南共形成35条推荐,涉及26个临床问题。
  • 推荐采用GRADE方法进行证据评价,但原文未逐条列出各推荐的GRADE等级标签。

临床怎么用

  • 原文未据此给出具体的临床操作推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Radioactive iodine-refractory differentiated thyroid cancer (RAIR-DTC) has become a challenge in clinical practice, particularly in China with a high incidence and undesirable survival outcome. Since the publication of first China consensus on the diagnosis and treatment of RAIR-DTC in 2019, significant and rapid advances have occurred in the field both in China and internationally. This guideline aims to inform Chinese clinicians, researchers, patients, and health policy makers on the latest evidence and recommendations, to further standardize the clinical diagnosis and treatment of RAIR-DTC. METHODS: The structured clinical questions addressed in this guideline were derived from clinical diagnostic and treatment processes, with references to study, prior guidelines, expert consensus, and systematic reviews, etc. The Grading of Recommendations Assessment, Development, and Evaluation (GRADE) was used for quantitative and qualitative evaluation of the evidence. The editorial process was completely independent of the guideline development group. RESULTS: The guideline addressed 26 clinical questions and formed 35 recommendations. In this guideline, the definition criteria for RAIR-DTC was optimized, prediction and identification was based on evidence including molecular testing, dynamic biochemical changes, and multimodal imaging. Comprehensive pre-treatment clinical evaluation was emphasized and tailored for individualized decision-making. The combination of systematic therapy and surgery, and the redifferentiation followed by RAI therapy were also reviewed and updated. Molecular imaging plays a unique role in the pre-assessing and therapeutic response evaluation for RAIR-DTC. CONCLUSIONS: We have updated and developed evidence-based recommendations with the aim of providing scientific, rigorous, and comprehensive guidance for the clinical diagnosis and treatment of RAIR-DTC patients in China. We hope to share our guideline with colleagues out of China, with the expectation of further comments and suggestions.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Lin YS, Wang RF, Huang R, et al. Chinese management guidelines for radioactive iodine-refractory differentiated thyroid cancer (2025 edition). Eur J Nucl Med Mol Imaging. 2025. PMID: 40128355. doi:10.1007/s00259-025-07222-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。